References
1. Yin, Zeyu et al. “Regulation of the Tec family of non-receptor
tyrosine kinases in cardiovascular disease.” Cell death discovery vol.
8,1 119. 16 Mar. 2022, doi:10.1038/s41420-022-00927-4
2. Tam, Constantine S et al. “Phase 1 study of the selective BTK
inhibitor zanubrutinib in B-cell malignancies and safety and efficacy
evaluation in CLL.” Blood vol. 134,11 (2019): 851-859.
doi:10.1182/blood.2019001160
3. Hillmen, Peter et al. “Zanubrutinib Versus Ibrutinib in
Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic
Lymphoma: Interim Analysis of a Randomized Phase III Trial.” Journal of
clinical oncology: official journal of the American Society of Clinical
Oncology, JCO2200510. 17 Nov. 2022, doi:10.1200/JCO.22.00510
4. Chamilos, Georgios et al. “Call for Action: Invasive Fungal
Infections Associated With Ibrutinib and Other Small Molecule Kinase
Inhibitors Targeting Immune Signaling Pathways.” Clinical infectious
diseases: an official publication of the Infectious Diseases Society of
America vol. 66,1 (2018): 140-148. doi:10.1093/cid/cix687
5. Estupiñán, H Yesid et al. “Comparative Analysis of BTK Inhibitors
and Mechanisms Underlying Adverse Effects.” Frontiers in cell and
developmental biology vol. 9 630942. 11 Mar. 2021,
doi:10.3389/fcell.2021.630942
6. Rogers, Kerry A et al. “Incidence of opportunistic infections during
ibrutinib treatment for B-cell malignancies.” Leukemia vol. 33,10
(2019): 2527-2530. doi:10.1038/s41375-019-0481
7. Maffei, Rossana et al. “Immunomodulatory effect of ibrutinib:
Reducing the barrier against fungal infections.” Blood reviews vol. 40
(2020): 100635. doi:10.1016/j.blre.2019.100635